Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)

NCT05103631 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT05103631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 17, 2021
Completion date
December 31, 2040
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

embryonal sarcoma of the liver, liposarcoma, liver cell carcinoma, malignant rhabdoid tumor, rhabdomyosarcoma, solid tumor, wilms tumor, yolk sac tumor